MF Saad, S Greco, K Osei, AJ Lewin, C Edwards, M … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Ragaglitazar in doses of 1, 4, and 10 mg resulted in a significant decrease from
baseline as compared with placebo in FPG (−48, −74, −77 mg/dl) and triglycerides (−40,
−62, −51%), free fatty acids (−36, −54, −62%), apolipoprotein B (−13, −29, −25%), LDL ... Cited by 8 - Related articles - All 2 versions
MF Saad, S Greco, K Osei, AJ Lewin, C Edwards, M … - Diabetes Care, 2004 - 万方数据资源系统 OBJECTIVE: Ragaglitazar is a novel insulin sensitizer with dual peroxisome proliferator-activated
receptor (PPAR)-gamma and PPAR-alpha stimulating activities that improve plasma glucose
and lipid profiles. The aim of the present dose-ranging study was to assess the efficacy ... Cited by 65 - Related articles - BL Direct - All 6 versions
- ►endojournals.org [PDF] L Hansen, CT Ekstrom, RT Palacios, M Anant, K … - Journal of Clinical …, 2006 - Endocrine Soc 1) Novo Nordisk A/S, Bagsværd, Denmark 2) Novo Nordisk Pharmaceuticals Inc, Princeton,
NJ, USA 3) Genaissance Pharmaceuticals, a wholly owned subsidiary of Clinical Data Inc, New
Haven, CT, USA 4) Royal Veterinary and Agricultural University, Copenhagen, Denmark Related articles
D Duffy, JF Keaney Jr, M Holbrook, N Gokce, PL … - Circulation, 2001 - pt.wkhealth.com Numerous prospective epidemiological studies have shown a strong inverse relationship between
HDL cholesterol (HDL-C) levels and coronary heart disease (CHD).1 Many controlled clinical
trials also demonstrate that treating patients who have low HDL-C with various lipid- ... Related articles - All 2 versions
[CITATION] Management of rosiglitazone related fluid retention
